Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

EPO Patent EP4499119A2 for Detecting Feline Lungworm

The European Patent Office has published patent application EP4499119A2, filed by IDEXX Laboratories, Inc., for methods, devices, and compositions for detecting feline lungworm. The patent application details specific classifications related to diagnostic methods and pharmaceutical compositions.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Indolizine compounds patent for mental disorders inflammation

Indolizine compounds patent for mental disorders inflammation

Routine Notice
Favicon for changeflow.com

Pharmaceutical Composition of Siponimod Patent Published

The European Patent Office (EPO) published patent application EP4633611A1 concerning a pharmaceutical composition of Siponimod on March 18, 2026. The patent application was filed by Synthon B.V. and lists NOGUEIRAS NIETO, Luis, ALVAREZ FERNANDEZ, Lisardo, and KUMAR, Rohit as inventors. This publication pertains to the designated states within the European Union.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Plectranthus Amboinicus Extract for Radiation Skin Disorders

The European Patent Office has published patent application EP4543425A1 concerning a Plectranthus Amboinicus extract for alleviating radiation-induced skin disorders. The patent is assigned to Oneness Biotech Co., Ltd. and lists LU, Kung-Ming, CHEN, Shyi-Gen, and CHEN, Jui-Ching as inventors.

Routine Notice Healthcare
Favicon for changeflow.com

HER2 Nanobody Preparation Method Patent

The European Patent Office has published patent application EP2024001510A1 concerning a preparation method for a HER2 nanobody and conjugate, filed by Fudan University. The patent application details specific IPC classifications related to antibodies, conjugates, and their therapeutic uses, particularly in treating cancer.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Bulletin: Solid State Forms of Zipalertinib

The European Patent Office published patent application EP4630120A1 concerning solid state forms of Zipalertinib and a process for its preparation. The application was filed by Assia Chemical Industries Ltd. and lists Pavel Kolesa, Jana Romanová, and Alexandr Jegorov as inventors.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Lipid Nanoparticles Lyophilization Methods and Compositions Patent

The European Patent Office has published patent application EP4633609A1 concerning methods and compositions for lyophilizing lipid nanoparticles. The patent was published on March 18, 2026, with Global Life Sciences Solutions Canada ULC listed as the applicant.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Publication: Anti-GDF 15 Antibody for Cancer Neoadjuvant Therapy

The European Patent Office has published patent application EP4634222A1 concerning an anti-GDF 15 antibody for the neoadjuvant therapy of cancer, filed by CatalYm GmbH. This publication details the invention and designated states for patent protection.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Publication EP4629997A1: ASBT Inhibitors for Renal Disease Treatment

The European Patent Office has published patent application EP4629997A1 concerning ASBT inhibitors for the treatment of renal diseases, filed by Albireo AB. The publication date is March 18, 2026.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Application: Antibodies Targeting Itga2 and Antibody-Drug Conjugates

The European Patent Office published patent application EP4545563A1 concerning antibodies targeting Itga2 and antibody-drug conjugates. The application lists Foreseen Technology (Beijing) Co., Ltd. and Foreseen Biotechnology (Shanghai) Co., Ltd. as applicants.

Routine Notice Pharmaceuticals

Showing 2811–2820 of 26,798 changes

1 280 281 282 283 284 2680

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.